

# ASCO 2015 Annual Meeting

## Illumination & Innovation: Transforming Data into Learning

### Study Presentations from US Oncology Research, The US Oncology Network and McKesson Specialty Health Affiliated Investigators\*

McCormick Place, Chicago, IL, May 29 – June 2, 2015

Oral Presentations			
Authors	Title	Abstract #	Date/Time
Lecia V. Sequist, Jonathan Wade Goldman, Heather A. Wakelee, D. Ross Camidge, Helena Alexandra Yu, Andrea Varga, Ben Solomon, Geoffrey R. Oxnard, Sai-Hong Ignatius Ou, Vassiliki Papadimitrakopoulou, Bo H. Chao, Stephen V. Liu, Karen L. Reckamp, <b>Alexander I. Spira</b> , Zofia Piotrowska, Darrin Despain, Chris Alan Karlovich, Sergey Yurasov, Jean-Charles Soria	Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts).	Abstract # 8001	Sunday, May 31, 8:12 AM to 8:24 AM; N Hall B1
Sai-Hong Ignatius Ou, Jin Seok Ahn, Luigi De Petris, Ramaswamy Govindan, James Chih-Hsin Yang, Brett Gordon Maxwell Hughes, Hervé Lena, Denis Moro-Sibilot, Alessandra Bearz, Santiago Viteri Ramirez, Tarek Mekhail, <b>Alexander I. Spira</b> , Ali Hassan Zeaiter, Walter Bordogna, Bogdana Balas, Sophie Golding, Peter N. Morcos, Dong-Wan Kim	Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673).	Abstract # 8008	Sunday, May 31, 10:24 AM to 10:36 AM; N Hall B1
Dennis J. Slamon, Sara A. Hurvitz, David Chen, Fabrice Andre, Ling-Ming Tseng, Guy Heinrich Maria Jerusalem, <b>Sharon Wilks</b> , Ruth O'Regan, Claudine Isaacs, Masakazu Toi, Howard A. Burris, Wei He, Markus Riester, Douglas Robinson, Tanya Taran, Luca Gianni	Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3.	Abstract # 512	Sunday, May 31, 12:18 PM to 12:30 PM; E Hall D2
<b>Alexander I. Spira</b> , Keunchil Park, Julien Mazières, Johan F. Vansteenkiste, Achim Rittmeyer, Marcus Ballinger, Daniel Waterkamp, Marcin Kowanetz, Ahmad Mokatrín, Louis Fehrenbacher	Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR).	Abstract # 8010	Sunday, May 31, 4:42 PM to 4:54 PM; E Hall D1
Nancy L. Bartlett, Charles M. Farber, <b>Christopher A. Yaseenchak</b> , Stephen Maxted Ansell, Ranjana H. Advani, Mark H. Knapp, Luis Fayad, <b>Kathryn S. Kolibaba</b> , Dipti Patel-Donnelly, <b>Mahesh Seetharam</b> , Habte Aragaw Yimer, Thomas John Manley, <b>John M. Burke</b> , Beata Holkova, L. Elizabeth Budde, Ahmad Sami Halwan	Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL).	Abstract # 8506	Monday, June 1, 9:45 AM to 12:45 PM; E450

**Bolded text:** Investigators affiliated with US Oncology Research, The US Oncology Network and/or McKesson Specialty Health.

\* Studies included are as of May 20, 2015.

Oral Presentations			
Authors	Title	Abstract #	Date/Time
Ranjana H. Advani, Ian Flinn, <b>Jeff Porter Sharman</b> , Catherine S. Magid Diefenbach, Kathryn S. Kolibaba, Oliver W. Press, Laurie Helen Sehn, Andy I. Chen, Gilles A. Salles, Herve Tilly, Bruce D. Cheson, Sarit E. Assouline, Martin H. Dreyling, Anton Hagenbeek, Pier Luigi Zinzani, Cheryl Jones, Yu-Waye Chu, Jamie Hirata, Michael Wenger, Franck Morschhauser	Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose level.	Abstract # 8503	Monday, June 1, 9:45 AM to 12:45 PM; E450
Julio Antonio Peguero, James A. Knost, Todd Michael Bauer, Matthew Hiram Taylor, <b>Fadi S. Braiteh</b> , Joseph Paul Eder, Howard Safran, Bert H. O'Neil, Ajjai Shivaram Alva, Lincoln Nadauld, Prashant Joshi, Flora Miranda, Rajinder Sidhu, Joy Ero, Eric Daniel Slosberg, Claudia Lebedinsky, Barinder Kang, Sudha Parasuraman, Sarina Anne Piha-Paul	Successful implementation of a novel trial model: The Signature program.	Abstract # 106	Monday, June 1, 9:50 AM to 10:05 AM; E Hall D
Daniel Peter Petrylak, Thomas Powles, Joaquim Bellmunt, <b>Fadi S. Braiteh</b> , Yohann Loriot, Cristina Cruz Zambrano, Howard A. Burris, Joseph W. Kim, Siew-leng Melinda Teng, Jean-Marie Bruey, Priti Hegde, Oyewale O. Abidoye, <b>Nicholas J. Vogelzang</b>	A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC).	Abstract # 4501	Monday, June 1, 9:57 AM to 10:09 AM; E Arie Crown Theater
Arlene Chan, Suzette Delalogue, <b>Frankie Ann Holmes</b> , Beverly Moy, Hiroji Iwata, Vernon J. Harvey, <b>Nicholas J. Robert</b> , Tajana Silovski, Erhan Gokmen, Gunter Von Minckwitz, Bent Ejlersen, Stephen K. L. Chia, Janine Mansi, Carlos H. Barrios, Michael Gnant, Alvin Wong, Richard Bryce, Bin Yao, Miguel Martin	Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET).	Abstract # 508	Monday, June 1, 10:24 AM to 10:36 AM; N Hall B1
Edith A. Perez, Ahmad Awada, <b>Joyce O'Shaughnessy</b> , Hope S. Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes	Phase III trial of etirinotecan pegol (EP) versus Treatment of Physician's Choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C): The BEACON study.	Abstract # 1001	Monday, June 1, 3:12 PM to 3:24PM; N Hall B1
Garrett Michael Frampton, Siraj Mahamed Ali, Mark Rosenzweig, Jonathan Wade Goldman, Carrie B. Lee, Jared Weiss, Jose A. Bufill, Ravi Salgia, Mohammad Jahanzeb, <b>Kartik Konduri</b> , Patrick M. Forde, Deborah Morosini, Jeffrey S. Ross, Sai-Hong Ignatius Ou, Roman Yelensky, Vincent A. Miller, Philip J. Stephens	Comprehensive genomic profiling (CGP) of advanced cancers to identify MET exon 14 alterations that confer sensitivity to MET inhibitors	Abstract # 11007	Monday, June 1, 3:00 PM to 6:00 PM; E450
Tiffany A. Traina, Kathy Miller, Denise A. Yardley, <b>Joyce O'Shaughnessy</b> , Javier Cortes, Ahmad Awada, Catherine Margaret Kelly, Maureen E. Trudeau, Peter Schmid, Luca Gianni, Laura Garcia-Estevéz, Rita Nanda, Foluso Olabisi Ademuyiwa, Stephen Chan, Joyce Leta Steinberg, Martha Elizabeth Blaney, Iulia Cristina Tudor, Hirdesh Uppal, Amy C. Peterson, Clifford A. Hudis	Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).	Abstract # 1003	Monday, June 1, 4:00 PM to 4:12 PM; N Hall B1
George D. Demetri, Margaret von Mehren, Robin Lewis Jones, Martee Leigh Hensley, Scott Schuetze, Arthur P. Staddon, Mohammed M. Milhem, Anthony D. Elias, Kristen N. Ganjoo, Hussein Abdul-Hassan Tawbi, Brian Andrew Van Tine, <b>Alexander I. Spira</b> , Andrew Peter Dean, Nushmia Z. Khokhar, Youn Choi Park, Roland Elmar Knoblauch, Trilok V. Parekh, Robert G. Maki, Shreyaskumar Patel	A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS).	Abstract # 10503	Monday, June 1, 4:00PM-4:12PM; S504

**Bolded text:** Investigators affiliated with US Oncology Research, The US Oncology Network and/or McKesson Specialty Health.

\*Studies included are as of May 20, 2015.

Poster Presentations			
Authors	Title	Abstract #	Date/Time
<b>Joyce O'Shaughnessy, Devchand Paul, Maren K. Levin,</b> Yunfei Wang, Nicholas N Hoke, Corinne Ramos	HER3 and paxillin signaling in ER+ HER2- metastatic breast cancer (MBC) patients receiving letrozole (L) vs letrozole plus dasatinib (L+D) in a randomized phase II trial.	Abstract # 517	Saturday, May 30, 8:00 AM to 11:30 AM; S Hall A
Sara M. Tolaney, Muralidhar Beeram, J. Thaddeus Beck, Alison Katherine Conlin, Elizabeth Claire Dees, Maura N. Dickler, Teresa L. Helsten, <b>Paul R. Conkling, William Jeffery Edenfield, Donald A. Richards,</b> P. Kellie Turner, Na Cai, Edward Michael Chan, Shubham Pant, <b>Carlos Becerra,</b> Kevin Kalinsky, Shannon Puhalla, Brent Neil Rexer, Howard A. Burris, Matthew P. Goetz	A phase Ib study of abemaciclib with therapies for metastatic breast cancer.	Abstract # 522	Saturday, May 30, 8:00 AM to 11:30 AM; S Hall A
Windy Marie Dean-Colomb, Clayton Yates, Sandeep K. Reddy, <b>Joyce O'Shaughnessy,</b> Sherri Z. Millis	Molecular profiling to identify genetic heterogeneity in synchronous and asynchronous breast cancers.	Abstract # 558	Saturday, May 30, 8:00 AM to 11:30 AM; S Hall A
Clayton Yates, Sherri Z. Millis, Sandeep K. Reddy, Zoran Gatalica, <b>Joyce O'Shaughnessy,</b> Windy Marie Dean-Colomb	Variations in measured ER, PR, and HER2 status in synchronous and asynchronous paired breast cancer (BC) tumors.	Abstract # 567	Saturday, May 30, 8:00 AM to 11:30 AM; S Hall A
<b>Frankie Ann Holmes,</b> Corinne Ramos, Nicholas N Hoke, <b>Maren K. Levin,</b> Virginia A. Espina, Lance A. Liotta, Kai Wang, Norma Alonzo Palma, <b>Joyce O'Shaughnessy</b>	HER3, PI3K, and JAK2 pathway activation on reverse phase protein microarray (RPMA) in HER2-amplified residual disease (RD) refractory to preoperative chemotherapy plus trastuzumab (H), lapatinib (L), or both (HL).	Abstract # 621	Saturday, May 30, 8:00 AM to 11:30 AM; S Hall A
Todd A. Hembrough, Fabiola Cecchi, Adele Blackler, Sheeno P Thyparambil, Jon Burrows, <b>Joyce O'Shaughnessy</b>	Proteomic analysis of primary and metastatic breast cancers and expression of the folate receptor as a potential drug target.	Abstract # 1045	Saturday, May 30, 8:00 AM to 11:30 AM; S Hall A
Sarina Anne Piha-Paul, James A. Knost, <b>Fadi S. Braiteh,</b> J. Thaddeus Beck, Daniel Lewis Spitz, <b>Steven W. Papish, Beth A. Hellerstedt,</b> Petros Nikolinos, Matthew Hiram Taylor, Sant P. Chawla, Lee Steven Schwartzberg, <b>David A. Smith,</b> Sebastian Szpakowski, Lening Zhang, Theresa White, Claudia Lebedinsky	Genomic Mutation Profiling (GMP) and Clinical Outcome of Patients Treated with Buparlisib (PI3K inhibitor) in the "Signature" Program.	Abstract # 2516	Saturday, May 30, 8:00 AM to 11:30 AM; S Hall A
Todd Michael Bauer, Michael McCleod, Jason Claud Chandler, George R. Blumenschein, Lee Steven Schwartzberg, Howard Burris, David Waterhouse, <b>Robert M. Jotte,</b> Maen Hussein, David R. Spigel, Dana Shelton Thompson, Xuemei Li, <b>Craig H. Reynolds</b>	An ongoing phase IIIb/IV safety trial of nivolumab (NIVO) in patients (pts) with advanced or metastatic non-small-cell lung cancer (NSCLC) who progressed after receiving 1 or more prior systemic regimens.	Abstract # 3013	Saturday, May 30, 8:00 AM to 11:30 AM; S Hall A Discussion Session: Saturday, May 30, 3:00 PM to 4:15 PM; S406
Scott N. Gettinger, Marcin Kowanetz, Hartmut Koeppen, Ignacio Ivan Wistuba, Mark Kockx, Edward E. Kadel, Naiyer A. Rizvi, <b>Alexander I. Spira,</b> Fred R. Hirsch, Zachary Boyd, Mitchell Denker, Alexandra Minn, David S. Shames, Alan Sandler, Daniel S. Chen, Priti S. Hegde, David R. Spigel	Molecular, immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody MPDL3280A.	Abstract # 3015	Saturday, May 30, 8:00 AM to 11:30 AM; S Hall A
Ingrid A. Mayer, Christian F. Singer, Peter A. Fasching, <b>Frankie Ann Holmes,</b> Michael Gnant, Laura G Estevez, Mario Campone, Michael Hubalek, Antonio C. Wolff, Jose Alejandro Perez-Fidalgo, Eric P. Winer, Gena Atalla-Vidam, Charu Kanwal, Lars Blumenstein, Nathalie Fretault, Ivan Diaz-Padilla, Carlos L. Arteaga	A Phase II study of the safety and efficacy of alpelisib or buparlisib plus letrozole in neoadjuvant treatment of postmenopausal women with HR+/HER2-, PIK3CA mutant or wild-type breast cancer.	Abstract # TPS633	Saturday, May 30, 8:00 AM to 11:30 AM; S Hall A

**Bolded text:** Investigators affiliated with US Oncology Research, The US Oncology Network and/or McKesson Specialty Health.

\*Studies included are as of May 20, 2015.

Poster Presentations			
Authors	Title	Abstract #	Date/Time
Denise A. Yardley, Javier Cortes, Robert E. Coleman, Pier Franco Conte, Adam Brufsky, <b>Joyce O'Shaughnessy</b> , Gail Lynn Shaw Wright, Janice F. Eakle, <b>Sharon Wilks</b> , Mikhail Shtivelband, Robyn R. Young, Carmelo Bengala, Huiling Li, Julie Ann Miller, Debora Barton, Nadia Harbeck	Weekly <i>nab</i> -paclitaxel ( <i>nab</i> -P) plus gemcitabine (gem) or carboplatin (carbo) vs gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC) in a phase 2/3 trial (tnAcity).	Abstract # TPS1106	Saturday, May 30, 8:00 AM to 11:30 AM; S Hall A
Jennifer Keating Litton, <b>Joanne Lorraine Blum</b> , Young-Hyuck Im, Miguel Martin, Lida A. Mina, Henri Hubert Roche, Hope S. Rugo, Fran Visco, Charlie Zhang, Nathalie Andrienne Lokker, Debra L. Lounsbury, Wolfgang Eiermann	A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA).	Abstract # TPS1107	Saturday, May 30, 8:00 AM to 11:30 AM; S Hall A
Mafalda Oliveira, Cristina Saura, Antonio Gonzalez-Martin, <b>Jay C. Andersen</b> , Julie Gottlieb Fisher, Isabel Calvo, Eva Ciruelos, Miquel Gil, Lorena De La Pena, Marta Llobet-Canela, YounJeong Choi, Shidong Jia, Sreenivasu Yalamanchili, Stina Mui Singel, Premal H. Patel, Jose Baselga, Steven J. Isakoff	FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (Ipat, GDC-0068) in combination with paclitaxel (Pac) as neoadjuvant treatment for early stage triple-negative breast cancer (TNBC).	Abstract # TPS1112	Saturday, May 30, 8:00 AM to 11:30 AM; S Hall A
John D. Powderly, Martin Gutierrez, Ding Wang, Young Kwang Chae, Daruka Mahadevan, <b>Fadi S. Braiteh</b> , Bonnie S. Glisson, Dongyue Fu, Michele Jordan, Jennifer T. McDevitt, Mark C. Lanasa, Brendan D. Curti	A Phase 1b/2, open-label study to evaluate the safety and tolerability of MEDI6469 in combination with immune therapeutic agents or therapeutic mAbs in patients with select advanced solid tumors or aggressive B-cell lymphomas.	Abstract # TPS3091	Saturday, May 30, 8:00 AM to 11:30 AM; S Hall A
A. Oliver Sartor, Daniel Celestino Fernandez, Michael J. Morris, Andrei Iagaru, Alan Brown, Fabio Almeida, Christopher Sweeney, Matthew Raymond Smith, Adam Dicker, Yu-Ning Wong, Neal D. Shore, Jeremy Gratt, Oana Petrenciuc, Joseph Germino, <b>Nicholas J. Vogelzang</b>	Ra-223 experience in pretreated patients: EAP setting.	Abstract # 5063	Saturday, May 30, 1:15 PM to 4:45 PM; S Hall A
Ting-Yim Lee, Chaan S. Ng, Zheng Zhang, Susanna Lee, Helga Marques, Kyle Burgers, Feng Su, Joseph Bauza, Robert S. Mannel, Joan L. Walker, Warner King Huh, Stephen C. Rubin, Paul DiSilvestro, Lainie P. Martin, John K. Chan, <b>Michael A. Bookman</b> , Robert L. Coleman	CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: An ECOG-ACRIN and NRG GOG study.	Abstract # 5522	Saturday, May 30, 1:15 PM to 4:45 PM; S Hall A Discussion Session: Saturday, May 30, 4:45 PM to 6:00 PM; E354b
Emmanuel S. Antonarakis, Adam S. Kibel, George W. Adams, Lawrence Ivan Karsh, Aymen Elfiky, Neal D. Shore, <b>Nicholas J. Vogelzang</b> , John M. Corman, Johnathan Cartwright Maher, Todd DeVries, Candice McCoy, Nadeem A. Sheikh, Charles G. Drake	Immune responses and clinical outcomes in STAND, a randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC) after local therapy failure.	Abstract # 5030	Saturday, May 30, 1:15 PM to 4:45 PM; S Hall A
<b>Nicholas J. Vogelzang</b> , Tomasz M. Beer, Jirina Bartunkova, Rostislav Kuklík, Kurt Miller, William K. Oh, Stephane Oudard, Hardev S. Pandha, A. Oliver Sartor, Radek Spisek, Niels Geert Borgstein, Winald R. Gerritsen	Autologous dendritic cell vaccination (DCVAC/PCa) added to docetaxel chemotherapy in a double-blind, randomized phase III trial (VIABLE) in men with advanced (mCRPC) prostate cancer.	Abstract # TPS5070	Saturday, May 30, 1:15 PM to 4:45 PM; S Hall A
Martin Chasen, Laszlo Urban, <b>Ian Schnadig</b> , Bernardo Leon Rapoport, Allen Poma, Sujata Arora, Rudolph M. Navari, Lee Steven Schwartzberg, Cesare Gridelli	Impact of rolapitant on quality of life (QoL) in patients (pts) receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC).	Abstract # 9615	Saturday, May 30, 1:15 PM to 4:45 PM; S Hall A

**Bolded text:** Investigators affiliated with US Oncology Research, The US Oncology Network and/or McKesson Specialty Health.

\*Studies included are as of May 20, 2015.

Poster Presentations			
Authors	Title	Abstract #	Date/Time
<b>Ian D. Schnadig, Manuel R. Modiano</b> , Allen Poma, Sujata Arora, Lee Steven Schwartzberg	Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving anthracycline-cyclophosphamide (AC)-based chemotherapy.	Abstract # 9618	Saturday, May 30, 1:15 PM to 4:45 PM; S Hall A
Paul Joseph Hesketh, Lee Steven Schwartzberg, <b>Manuel R. Modiano</b> , Sujata Arora, Allen Poma, <b>Ian D. Schnadig</b>	Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in moderately emetogenic therapy (MEC).	Abstract # 9622	Saturday, May 30, 1:15 PM to 4:45 PM; S Hall A
Anthony Mato, Christopher Flowers, <b>Charles Michael Farber</b> , Mark Adam Weiss, Thomas J. Kipps, Mark Kozloff, Chadi Nabhan, Ian Flinn, David L. Grinblatt, Nicole Lamanna, Kristen A. Sullivan, Pavel Kiselev, E. Dawn Flick, Kenneth A. Foon, Arlene S. Swern, <b>Jeff Porter Sharman</b>	Prognostic testing patterns in CLL pts treated in U.S. practices from the Connect CLL registry.	Abstract # 7013	Sunday, May 31, 8:00 AM to 11:30 AM; S Hall A
James R. Berenson, Alan Cartmell, Alberto Bessudo, <b>Roger M. Lyons</b> , Wael A. Harb, Dimitrios Tzachanis, Morton Coleman, Ralph V. Bocchia, <b>Robert M. Rifkin</b> , Priti Patel, Sandra Dixon, Jesus G. Berdeja	Updated results from CHAMPION-1, a phase I/II study investigating weekly carfilzomib with dexamethasone for patients (Pts) with relapsed or refractory multiple myeloma (RRMM).	Abstract # 8527	Sunday, May 31, 8:00 AM to 11:30 AM; S Hall A Discussion Session Sunday, May 31, 4:30 PM to 5:45 PM; E354b
Daniel Jeffrey Landsburg, Adam Matthew Petrich, Jeremy S. Abramson, Aliyah Sohani, Oliver W. Press, Ryan Daniel Cassaday, Julio C. Chavez, Kevin W. Song, Andrew David Zelenetz, <b>Mitul Gandhi</b> , Namrata Mahendra Shah, Timothy Fenske, Jesse Jasso, L Jeffrey Medeiros, David T Yang, Chadi Nabhan	Analysis of "double-hit" lymphoma cases by genetic subtype.	Abstract # 8543	Sunday, May 31, 8:00 AM to 11:30 AM; S Hall A
Jacqueline Claudia Barrientos, Paolo Ghia, John Pagel, Gilles A. Salles, <b>Jeff Porter Sharman</b> , Stephan Stilgenbauer, Oksana Gurtovaya, Yeonhee Kim, Betsy Philip, Andrew David Zelenetz	Outcomes of anticoagulant (AC) or antiplatelet (AP) use in patients (pts) with chronic lymphocytic leukemia (CLL) or indolent non-Hodgkin's lymphoma (iNHL) in idelalisib (IDELA) trials.	Abstract # 8563	Sunday, May 31, 8:00 AM to 11:30 AM; S Hall A
Jacob Laubach, Noopur S. Raje, Andrew Jenho Yee, Philippe Armand, Robert L. Schlossman, Jacalyn Rosenblatt, Jacquelyn Ann Hedlund, Michael Gary Martin, <b>Craig H. Reynolds</b> , Kenneth H. Shain, <b>Ira Zackon</b> , Laura Stampleman, Erica Boswell, Stacey Chuma, Rebecca Liguori, Damian Handisides, Stew Kroll, Kenneth Carl Anderson, Paul G. Richardson, Irene M. Ghobrial	Preliminary safety and efficacy of evofosfamide (TH-302), an investigational hypoxia-activated prodrug, combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RR MM).	Abstract # 8579	Sunday, May 31, 8:00 AM to 11:30 AM; S Hall A
Jatin J. Shah, Rafat Abonour, Brian G. Durie, Jayesh Mehta, <b>Mohit Narang</b> , Howard R. Terebelo, Cristina Gasparetto, Kathleen Toomey, James W. Hardin, Shankar Srinivasan, Gail Larkins, Rosanna J. Ricafort, Yasir M. Nagarwala, <b>Robert M. Rifkin</b>	Overall survival in newly diagnosed MM patients with del(17p): A report from the Connect MM Registry.	Abstract # 8582	Sunday, May 31, 8:00 AM to 11:30 AM; S Hall A
David Jacob Andorsky, Paula J. Franson, Jorge L Mouro, Jiahui Li, Kenneth A. Foon, <b>Jeff Porter Sharman</b> , MAGNIFY Trial Investigators	MAGNIFY: A randomized, phase 3b trial in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) investigating lenalidomide plus rituximab (R2) induction followed by maintenance R2 followed by lenalidomide versus R2 induction followed by rituximab (R) maintenance.	Abstract #TPS8606	Sunday, May 31, 8:00 AM to 11:30 AM; S Hall A

**Bolded text:** Investigators affiliated with US Oncology Research, The US Oncology Network and/or McKesson Specialty Health.

\*Studies included are as of May 20, 2015.

Poster Presentations			
Authors	Title	Abstract #	Date/Time
Jacqueline Claudia Barrientos, Steven Coutre, Sven De Vos, Ian Flinn, Nina D. Wagner-Johnston, Marshall T. Schreeder, <b>Jeff Porter Sharman</b> , Thomas E. Boyd, Kanti Roop Rai, John Leonard, Bess Sorensen, Anthony Viggiano, Thomas Michael Jahn, Richard R. Furman	Long-term follow-up of a phase Ib trial of idelalisib (IDELA) in combination with chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory (R/R) CLL including pts with del17p/TP53 mutation.	Abstract # 7011	Sunday, May 31, 8:00 AM to 11:30 AM; S Hall A
Kristen Keon Ciombor, <b>William Jeffery Edenfield</b> , Joleen Marie Hubbard, Peter J. O'Dwyer, <b>Carlos Becerra</b> , Tim Larson, <b>Alexander I. Spira</b> , Axel Grothey, Divya Manoharan, Wei Li, Youzhi Li, Laura Borodyansky, Chiang Li, Tanios S. Bekaii-Saab	A phase Ib/II study of cancer stem cell inhibitor BBI608 administered with panitumumab in KRAS wild-type (wt) patients (pts) with metastatic colorectal cancer (mCRC) following progression on anti-EGFR therapy.	Abstract # 3617	Monday, June 1, 8:00 AM to 11:30 AM; S Hall A
<b>Carlos Becerra</b> , Joe Stephenson, Derek J. Jonker, <b>Allen Lee Cohn</b> , Timothy R. Asmis, Tanios S. Bekaii-Saab, <b>Paul R. Conkling</b> , <b>Lawrence E. Garbo</b> , Heinz-Josef Lenz, <b>Donald A. Richards</b> , <b>Alexander I. Spira</b> , Sameh Mikhail, Rachel Anne Goodwin, Harry H. Yoon, Stephanie Hume, Matthew Hitron, Chiang Li	Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.	Abstract # 4069	Monday, June 1, 8:00 AM to 11:30 AM; S Hall A
Maria Catherine Pietanza, <b>Alexander I. Spira</b> , <b>Robert M. Jotte</b> , Shirish M. Gadgeel, Alain C. Mita, Lowell L. Hart, <b>W Larry Gluck</b> , Anne C. Chiang, Stephen V. Liu, Ann M. Kapoun, Lu Xu, Dawn Hill, Jakob Dupont, David R. Spigel, Lei Zhou	Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).	Abstract # 7508	Monday, June 1, 8:00 AM to 11:30 AM; S Hall A Discussion Session Monday, June 1, 1:15 PM to 2:30 PM; E Hall D2
Helena Alexandra Yu, Geoffrey R. Oxnard, <b>Alexander I. Spira</b> , Leora Horn, Jared Weiss, Yan Feng, Howard Jack West, Giuseppe Giaccone, Tracey L. Evans, Ronan Joseph Kelly, Tanya Fleege, Srinivasu Poondru, Fei Jie, Koji Aoyama, Margaret A. Foley, Debbie Whitcomb, Anne Therese Keating, Andrew P. Krivoshik	Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC.	Abstract # 8083	Monday, June 1, 8:00 AM to 11:30 AM; S Hall A Discussion Session Monday, June 1, 1:15 PM to 2:30 PM; E Hall D2
David R. Fogelman, Mark D. Kochenderfer, Gene Brian Saylor, <b>Fadi S. Braithe</b> , John J. Nemunaitis, <b>Allen Lee Cohn</b> , Peter O'Neill, Li Zhou, Julie C. Switzky, Albert Assad, Johanna C. Bendell	Phase II study of ruxolitinib with regorafenib for relapsed/refractory (r/r) metastatic colorectal cancer (mCRC).	Abstract # TPS3623	Monday, June 1, 8:00 AM to 11:30 AM; S Hall A
Vinay K. Puduvalli, Jing Wu, Ying Yuan, Terri S. Armstrong, <b>Morris D. Groves</b> , Jeffrey J. Raizer, Pierre Giglio, Howard Colman, David M. Peereboom, Tobias Walbert, Nicholas George Avgeropoulos, Fabio Massaiti Iwamoto, Marc C. Chamberlain, Nina Paleologos, Karen L. Fink, Ryan Merrell, W. K. Alfred Yung, Mark R. Gilbert	Brain Tumor Trials Collaborative Bayesian Adaptive Randomized Phase II trial of bevacizumab plus vorinostat versus bevacizumab alone in adults with recurrent glioblastoma (BTTC-1102).	Abstract # 2012	Display: Monday, June 1, 1:15 PM to 4:45 PM; S Hall A Discussion: Monday, June 1, 4:45 PM to 6:00 PM; S100A
Marta Penas-Prado, Kenneth R. Hess, Victor A. Levin, John Frederick De Groot, Howard Colman, <b>Morris D. Groves</b> , Charles A. Conrad, Monica Elena Loghin, Kathy Hunter, Mark R. Gilbert, W. K. Alfred Yung, Vinay K. Puduvalli	Phase I study of vorinostat combined with isotretinoin and temozolomide in adults with recurrent malignant gliomas.	Abstract # 2039	Monday, June 1, 1:15 PM to 4:45 PM; S Hall A
Howard Colman, Frank Mott, <b>Alexander I. Spira</b> , Theodore S. Johnson, Yousef Zakharia, Nicholas N. Vahanian, Charles J. Link, Eugene Paul Kennedy, Ramses F. Sadek, David Munn, Olivier Rixe	A phase Ib/2 study of the combination of the IDO pathway inhibitor indoximod and temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors: Safety analysis and preliminary efficacy of the phase Ib component.	Abstract # 2070	Monday, June 1, 1:15 PM to 4:45 PM; S Hall A

**Bolded text:** Investigators affiliated with US Oncology Research, The US Oncology Network and/or McKesson Specialty Health.

\* Studies included are as of May 20, 2015.

Poster Presentations			
Authors	Title	Abstract #	Date/Time
Przemyslaw Twardowski, Melissa Plets, Elizabeth R. Plimack, Neeraj Agarwal, Catherine M. Tangen, <b>Nicholas J. Vogelzang</b> , Ian Murchie Thompson, Primo Lara	SWOG 1107: Parallel (randomized) phase II evaluation of tivantinib (ARQ-197) and tivantinib in combination with erlotinib in patients (Pts) with papillary renal cell carcinoma (pRCC).	Abstract # 4523	Monday, June 1, 1:15 PM to 4:45 PM; S Hall A Discussion Session Monday, June 1, 4:45 PM to 6:00 PM; E Arie Crown Theater
Martin Henner Voss, Andrea Coates, Edward Graeme Garmey, Naomi B. Haas, <b>Thomas Hutson</b> , Stephen Michael Keefe, Robert Motzer, Anthony Piscitelli, <b>Nicholas J. Vogelzang</b> , Robert A. Figlin	Randomized phase 2 study to assess the safety and efficacy of CRLX101 in combination with bevacizumab in patients (pts.) with metastatic renal cell carcinoma (RCC) versus standard of care (SOC).	Abstract # TPS4579	Monday, June 1, 1:15 PM to 4:45 PM; S Hall A
Thai Huu Ho, Sherri Z. Millis, David Bryant, Zoran Gatalica, Sandeep K. Reddy, Melissa L. Stanton, Erik P. Castle, Richard Wayne Joseph, <b>Nicholas J. Vogelzang</b>	Molecular analysis of sarcomatoid renal cell carcinoma (sRCC).	Abstract # 4556	Monday, June 1, 1:15 PM to 4:45 PM; S Hall A
Monika Joshi, Sherri Z. Millis, Donald L. Lamm, Sandeep K. Reddy, Sheldon L. Holder, <b>Nicholas J. Vogelzang</b> , Joseph J. Drabick	Molecular characterization of bladder cancer in smokers versus non-smokers.	Abstract # 4528	Monday, June 1, 1:15 PM to 4:45 PM; S Hall A

Publication		
Authors	Title	Abstract #
<b>Marcus A. Neubauer, J. Russell Hoverman, Jad Hayes, Kathryn Eagye, Melissa Jameson, Mitra Abdullahpour, Cynthia Taniguchi</b> , Michael A. Kolodziej, Maria Sipala, Amy Supraner	Telephonic Advance Care Planning (ACP) with Medicare patients with advanced cancer: Interim program results.	Abstract # e17712
<b>Nicholas J. Vogelzang</b> , Lina Asmar, Jun Tang, Mark Yap, Mary Beth Todd, Yvette Ng, Maneesha Mehra, <b>Debra A. Patt</b>	Abiraterone acetate followed by enzalutamide in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) treated in the US Oncology Community Setting.	Abstract # e16061
Sachdev P. Thomas, Lauren Jacobson, <b>Fadi S. Braitheh</b> , Anthony R. Victorio, Karen Ann Cherkis, Theresa N. Operana, Nichole Renee Blatner, Brock Schroeder, Catherine A. Schnabel	Molecular diagnosis with the 92-gene assay (92-GA) and decision-impact on treatment: Final results from a prospective, multi-disciplinary study.	Abstract # e15206
James E. Signorovitch, Sumanta Kumar Pal, William M Reichmann, Nanxin Li, Zhimei Liu, Jose Ricardo Perez, <b>Nicholas J. Vogelzang</b> , Eric Jonasch	Comparative effectiveness of everolimus (EVE) and axitinib (AXI) for 2nd targeted therapy (TT) of metastatic renal cell carcinoma (mRCC) in the US: A retrospective chart review.	Abstract # e15612
Celestia S. Higano, A. Oliver Sartor, <b>Nicholas J. Vogelzang</b> , Shaker R. Dakhil, Raoul S. Concepcion, Christopher Michael Pieczonka, Jeffrey L. Vacirca, Ronald F. Tutrone, Carl A. Olsson, David F. Penson, Craig Biggs, Jennifer Susan Lill, Todd E. Gray, Candice McCoy, Matthew R. Cooperberg, Andrew J. Armstrong.	Administration of sipuleucel-T (sip-T) infusions (infs) outside of the clinical trial setting: Data from the PROCEED registry.	Abstract # e16027
Christopher Sweeney, A. Oliver Sartor, <b>Nicholas J. Vogelzang</b> , Neal D. Shore, Paul Cislo, Keith Bangerter, Michael J. Morris	Effect of radium-223 dichloride (Ra-223) on pain from US EAP.	Abstract # e16086
Chris Parker, <b>Nicholas J. Vogelzang</b> , A. Oliver Sartor, Robert E. Coleman, Irene Skjorestad, Fang Fang, Sten Nilsson	3-year posttreatment follow-up of radium-223 dichloride (Ra-223) safety in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study.	Abstract # e16102
Samuel Ejadi, <b>Nicholas J. Vogelzang</b> , A. Oliver Sartor, Andrew Habbe, Binh Nguyen, Anthony W. Tolcher	Phase 1 study of the PSMA-tubulysin small-molecule drug conjugate EC1169 in pts with metastatic castrate-resistant prostate cancer (mCRPC).	Abstract # e13527

**Bolded text:** Investigators affiliated with US Oncology Research, The US Oncology Network and/or McKesson Specialty Health.

\* Studies included are as of May 20, 2015.

Publication		
Authors	Title	Abstract #
Jose Ricardo Perez, Sumanta Kumar Pal, James E. Signorovitch, William M. Reichmann, Nanxin Li, Zhimei Liu, Eric Jonasch, <b>Nicholas J. Vogelzang</b>	Changes in treatment patterns among patients receiving at least two targeted therapies for metastatic renal cell carcinoma (mRCC) in the US: A comparison of retrospective chart reviews conducted in 2012 and 2014.	Abstract # e15620
Kathleen Toomey, <b>Robert Rifkin</b> , et. al.	Characteristics and survival in African American newly diagnosed multiple myeloma patients: A Report from the Connect MM Registry.	Abstract # e19529
Rita Nanda, <b>Sharon Wilks, Manuel R. Modiano, Alexander I. Spira, Carlos Becerra</b> , Jackie Walling, Dat Nguyen, Gabrielle Baker, Suzanne D. Conzen	Mifepristone (MIFE), a glucocorticoid receptor (GR) antagonist, in combination with eribulin (E) in advanced solid tumors: A phase 1 study with dose expansion in patients (pts) with triple-negative breast cancer (TNBC).	Abstract # e12070
Steven Coutre, Jacqueline Claudia Barrientos, Jennifer R. Brown, Sven De Vos, Richard R. Furman, Michael J. Keating, Susan Mary O'Brien, John M. Pagel, <b>Jeff Porter Sharman</b> , Andrew David Zelenetz, Terry Newcomb, Yoonjin Cho, Christopher Aguilar, Lyndah Dreiling	Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials.	Abstract # e18030
Shringi Sharma, Feng Jin, Meihua Wu, Michelle Robeson, Esteban Abella-Dominicis, <b>Jeff Porter Sharman</b> , Srini Ramanathan	Exposure-response analysis from a Phase 2 study of the Syk inhibitor entospletinib in patients with relapsed or refractory hematologic malignancies.	Abstract # e13584

Education		
Authors	Title	Date/Time
<b>Marcus Neubauer</b>	Value in Lung Cancer Care: The Use of Standardized Pathways and Cost-Effectiveness.	Saturday, May 30, 1:55 PM to 2:15 PM; E Hall D1
<b>Stuart Staggs</b>	ICD-10 Practical Implementation: Before and after October 1, 2015.	Sunday, May 31, 4:30 PM to 5:45 PM; S102
<b>Nicholas J. Vogelzang</b>	Practical Considerations in the Treatment of the Frail Patient with Bladder Cancer.	Monday, June 1, 8:00 AM to 9:15 AM; E Hall D2

**Bolded text:** Investigators affiliated with US Oncology Research, The US Oncology Network and/or McKesson Specialty Health.

\*Studies included are as of May 20, 2015.

### Learn More Today

To learn more about US Oncology Research, please contact us.

For Pharmaceutical & Biotech customers:

call 866.951.2774, email us at [USOncologyResearch@mckesson.com](mailto:USOncologyResearch@mckesson.com), or visit [www.McKessonSpecialtyHealth.com/PharmaBiotech](http://www.McKessonSpecialtyHealth.com/PharmaBiotech)

For Providers:

call 800.482.6700, email us at [msh.providers@mckesson.com](mailto:msh.providers@mckesson.com), or visit [www.usoncology.com](http://www.usoncology.com)